scholarly journals TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer

2016 ◽  
Vol 27 ◽  
pp. vi115
Author(s):  
U. Banerji ◽  
B. Basu ◽  
J.F. Spicer ◽  
R. Wilson ◽  
E. Hall ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase I ◽  
Phase I Study ◽  
Weekly Paclitaxel ◽  
High Grade ◽  
Serous Ovarian Cancer

Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2510-2510 ◽  
Author(s):  
Ursula Matulonis ◽  
Gerburg M. Wulf ◽  
Michael J. Birrer ◽  
Shannon Neville Westin ◽  
Philippa Quy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Phase I ◽  
Triple Negative Breast Cancer ◽  
Phase I Study ◽  
Triple Negative ◽  
High Grade ◽  
Serous Ovarian Cancer

Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5514-5514 ◽  
Author(s):  
Victoria L. Chiou ◽  
Elise C. Kohn ◽  
Christina M. Annunziata ◽  
Lori M. Minasian ◽  
Stan Lipkowitz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase I ◽  
Genetic Risk ◽  
Parp Inhibitor ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Heavily Pretreated

scholarly journals Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk

Oncotarget ◽  
2019 ◽  
Vol 10 (30) ◽  
pp. 2855-2868 ◽  
Author(s):  
Erika J. Lampert ◽  
John L. Hays ◽  
Elise C. Kohn ◽  
Christina M. Annunziata ◽  
Lori Minasian ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase I ◽  
Genetic Risk ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Heavily Pretreated
Sign in / Sign up

Export Citation Format

Share Document